Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 9 of 9
Full-Text Articles in Medicine and Health Sciences
Novel Implications Of Lingo-1 And Its Signalling Partners In The Dorsolateral Prefrontal Cortex In Schizophrenia, Jessica L. Andrews, Kelly A. Newell, Xu-Feng Huang, Francesca Fernandez-Enright
Novel Implications Of Lingo-1 And Its Signalling Partners In The Dorsolateral Prefrontal Cortex In Schizophrenia, Jessica L. Andrews, Kelly A. Newell, Xu-Feng Huang, Francesca Fernandez-Enright
Illawarra Health and Medical Research Institute
No abstract provided.
Expression Of Proteins Within The Nogo Receptor Complex Are Altered In The Dorsolateral Prefrontal Cortex In Schizophrenia, J Andrews, K Newell, F Fernandez
Expression Of Proteins Within The Nogo Receptor Complex Are Altered In The Dorsolateral Prefrontal Cortex In Schizophrenia, J Andrews, K Newell, F Fernandez
Faculty of Science, Medicine and Health - Papers: part A
No abstract provided.
Metabotropic Glutamate Receptor 5 Binding And Protein Expression In Schizophrenia And Following Antipsychotic Drug Treatment, Natalie Matosin, Elisabeth Frank, Chao Deng, Xu-Feng Huang, Kelly A. Newell
Metabotropic Glutamate Receptor 5 Binding And Protein Expression In Schizophrenia And Following Antipsychotic Drug Treatment, Natalie Matosin, Elisabeth Frank, Chao Deng, Xu-Feng Huang, Kelly A. Newell
Faculty of Science, Medicine and Health - Papers: part A
Metabotropic glutamate receptor 5 (mGluR5) has been identified as a potential therapeutic target for schizophrenia, primarily due to its ability to indirectly modulate glutamatergic signalling through the NMDA receptor (NMDAR). Despite its potential, molecular studies characterising mGluR5 in schizophrenia are limited. We therefore aimed to determine if the mGluR5 binding site or protein levels were altered in schizophrenia or by current antipsychotics. Using in-situ radioligand binding and immunoblot, we measured [3H]MPEP binding to mGluR5 and mGluR5 protein density in the post-mortem dorsolateral prefrontal cortex (DLPFC; BA46) of 37 schizophrenia and 37 matched control subjects. Subsequently, we measured [3H]MPEP binding in …
Neuregulin-1 Signalling And Antipsychotic Treatment: Potential Therapeutic Targets In A Schizophrenia Candidate Signalling Pathway, Chao Deng, Bo Pan, Martin Engel, Xu-Feng Huang
Neuregulin-1 Signalling And Antipsychotic Treatment: Potential Therapeutic Targets In A Schizophrenia Candidate Signalling Pathway, Chao Deng, Bo Pan, Martin Engel, Xu-Feng Huang
Faculty of Science, Medicine and Health - Papers: part A
Identifying the signalling pathways underlying the pathophysiology of schizophrenia is an essential step in the rational development of new antipsychotic drugs for this devastating disease. Evidence from genetic, transgenic and post-mortem studies have strongly supported neuregulin-1 (NRG1)-ErbB4 signalling as a schizophrenia susceptibility pathway. NRG1-ErbB4 signalling plays crucial roles in regulating neurodevelopment and neurotransmission, with implications for the pathophysiology of schizophrenia. Post-mortem studies have demonstrated altered NRG1-ErbB4 signalling in the brain of schizophrenia patients. Antipsychotic drugs have different effects on NRG1-ErbB4 signalling depending on treatment duration. Abnormal behaviours relevant to certain features of schizophrenia are displayed in NRG1/ErbB4 knockout mice or …
Diabetes And Cognitive Deficits In Chronic Schizophrenia: A Case-Control Study, Mei Han, Xu-Feng Huang, Da Chun Chen, Meihong Xiu, Thomas R. Kosten, Xiang Yang Zhang
Diabetes And Cognitive Deficits In Chronic Schizophrenia: A Case-Control Study, Mei Han, Xu-Feng Huang, Da Chun Chen, Meihong Xiu, Thomas R. Kosten, Xiang Yang Zhang
Faculty of Science, Medicine and Health - Papers: part A
Cognitive impairment occurs in both schizophrenia and diabetes. There is currently limited understanding whether schizophrenia with diabetes has more serious cognitive deficits than schizophrenia without diabetes or diabetes only. This study assessed cognitive performance in 190 healthy controls, 106 diabetes only, 127 schizophrenia without diabetes and 55 schizophrenia with diabetes. This study was conducted from January 2008 to December 2010. Compared to healthy controls, all patient groups had significantly decreased total and five index RBANS scores (all p<0.01-p
Molecular Evidence Of N-Methyl-D-Aspartate Receptor Hypofunction In Schizophrenia, C S. Weickert, S J. Fung, V S. Catts, P R. Schofield, K M. Allen, L T. Moore, Kelly A. Newell, D Pellen, Xu-Feng Huang, S V. Catts, T W Weickert
Molecular Evidence Of N-Methyl-D-Aspartate Receptor Hypofunction In Schizophrenia, C S. Weickert, S J. Fung, V S. Catts, P R. Schofield, K M. Allen, L T. Moore, Kelly A. Newell, D Pellen, Xu-Feng Huang, S V. Catts, T W Weickert
Faculty of Science, Medicine and Health - Papers: part A
Blockade of N-methyl-D-aspartate receptors (NMDARs) produces behavior in healthy people that is similar to the psychotic symptoms and cognitive deficits of schizophrenia and can exacerbate symptoms in people with schizophrenia. However, an endogenous brain disruption of NMDARs has not been clearly established in schizophrenia. We measured mRNA transcripts for five NMDAR subunit mRNAs and protein for the NR1 subunit in the dorsolateral prefrontal cortex (DLPFC) of schizophrenia and control (n=74) brains. Five NMDAR single-nucleotide polymorphisms (SNPs) previously associated with schizophrenia were tested for association with NMDAR mRNAs in postmortem brain and for association with cognitive ability in an antemortem cohort …
Does Food Addiction Heighten The Propensity Towards Obesity In Schizophrenia?, N Pai, S I. Vella
Does Food Addiction Heighten The Propensity Towards Obesity In Schizophrenia?, N Pai, S I. Vella
Faculty of Science, Medicine and Health - Papers: part A
Abstract of poster that presented at the 15th ISAM Annual Meeting: Managing Addiction through Evidence-Based Medical and Psychosocial Interventions, 21-23 November 2013, Kuala Lumpur, Malaysia.
Mapping The Pathophysiology Of Schizophrenia: Interactions Between Multiple Cellular Pathways, Chao Deng, Brian Dean
Mapping The Pathophysiology Of Schizophrenia: Interactions Between Multiple Cellular Pathways, Chao Deng, Brian Dean
Illawarra Health and Medical Research Institute
Schizophrenia is a complex disorder involving dysregulation of multiple pathways in its pathophysiology. Dopaminergic, glutamatergic and GABAergic neurotransmitter systems are affected in schizophrenia and interactions between these receptors contribute to the pathophysiology of the disease. Deficits in acetylcholine muscarinic receptors have been identified in a sub-group of individuals with schizophrenia. Inflammation has also been found to play a major role in the development and exacerbation of psychotic symptoms in schizophrenia. Additionally, evidence from genetic, post-mortem and animal studies over the past decade has identified a number of susceptibility factors for schizophrenia, including neuregulin 1 (Nrg1) and its receptor ErbB4, disrupted-in-schizophrenia-1 …
In Vivo Pharmacological Evaluations Of Novel Olanzapine Analogues In Rats: A Potential New Avenue For The Treatment Of Schizophrenia, Somayeh Jafari, Xu-Feng Huang, Jessica L. Andrews, Francesca Fernandez-Enright
In Vivo Pharmacological Evaluations Of Novel Olanzapine Analogues In Rats: A Potential New Avenue For The Treatment Of Schizophrenia, Somayeh Jafari, Xu-Feng Huang, Jessica L. Andrews, Francesca Fernandez-Enright
Illawarra Health and Medical Research Institute
Olanzapine (Olz) is one of the most effective antipsychotic drugs commonly used for treating schizophrenia. Unfortunately, Olz administration is associated with severe weight gain and metabolic disturbances. Both patients and clinicians are highly interested in the development of new antipsychotics which are as effective as atypical antipsychotics but which have a lower propensity to induce metabolic side effects. In the present study, we examined two new derivatives of Olz; OlzEt (2-ethyl-4-(4′-methylpiperazin-1′-yl)-10Hbenzo[b]thieno[2,3-e][1,4]diazepine), and OlzHomo (2-ethyl-4-(4′-methyl-1′,4′-diazepan-1′-yl)-10H-benzo[b]thieno[2,3-e] [1,4]diazepine), for their tendency to induce weight gain in rats. Weight gain and metabolic changes were measured in female Sprague Dawley rats. Animals were treated orally …